On October 7, 2024, CytoMed Therapeutics announced co-funding support from Singapore's Ministry of Health for its Phase I ANGELICA clinical trial using CAR-T cells, and completed the acquisition of a licensed cord blood bank in Malaysia, enhancing its cell therapy strategy.